Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

KFDA Clearance for StoneChecker Software

20 Jan 2020 07:00

RNS Number : 2389A
IQ-AI Limited
20 January 2020
 

IQ-AI Ltd

("IQ-AI" or the "Company")

 

IQ-AI Announce Korean FDA Clearance to Market for StoneChecker Software, and GMP certification for Imaging Biometrics, and the appointment of Dr Balaji Ganeshan as consultant

 

IQ-AI has received notification that the Korean FDA (KFDA) has cleared StoneChecker Software for marketing in the Republic of Korea, a key market for high-tech medical imaging hardware and software. In addition, Imaging Biometrics (IB) has received GMP certification.

 

Trevor Brown, Chief Executive of IQ-AI commented, "We are delighted that StoneChecker Software has received KFDA approval for marketing in the Republic of Korea, our Korean distributor's marketing plans can now be fully implemented. It also gives me great pleasure to welcome back Dr Balaji Ganeshan to the team. Dr Ganeshan, an exceptionally innovative medical imaging entrepreneur and scientist, has invaluable expertise and ideas in a number of key technologies relevant to the Company. He will be working as a consultant for IB."

 

Dr Ganeshan, who was previously a director of StoneChecker Software, holds the position of Senior Research Associate at the Institute of Nuclear Medicine at University College London and is a prolific academic scientist in the area of medical image analysis. 

 

Dr. Balaji Ganeshan commented, "I very much look forward to working alongside Trevor Brown again, and also the team at IB, on all the technologies that IQ-AI have access to."

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

-ENDS-

 

For further information, please contact:

IQ-AI Limited

Trevor Brown/Michael Schmainda

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

About IQ-AI Ltd 

IQ-AI, Ltd, the parent company of StoneChecker® and Imaging Biometrics®, is focused on advanced and state of the art medical software and services. Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. Please visit www.imagingbiometrics.com for further information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRSFFFAUESSEEF
Date   Source Headline
20th Nov 20209:00 amRNSPrice Monitoring Extension
17th Nov 20201:26 pmRNSDirector/PDMR Shareholding
13th Nov 202011:05 amRNSSecond Price Monitoring Extn
13th Nov 202011:00 amRNSPrice Monitoring Extension
12th Nov 20204:41 pmRNSSecond Price Monitoring Extn
12th Nov 20204:36 pmRNSPrice Monitoring Extension
12th Nov 20202:01 pmRNSPrice Monitoring Extension
12th Nov 20207:00 amRNSCorrection: Director Dealing and CLN Conversion
11th Nov 20207:00 amRNSDirector Dealing and Conversion of Loan Notes
10th Nov 20204:35 pmRNSPrice Monitoring Extension
10th Nov 20202:06 pmRNSSecond Price Monitoring Extn
10th Nov 20202:00 pmRNSPrice Monitoring Extension
10th Nov 202011:06 amRNSSecond Price Monitoring Extn
10th Nov 202011:01 amRNSPrice Monitoring Extension
9th Nov 20202:06 pmRNSSecond Price Monitoring Extn
9th Nov 20202:00 pmRNSPrice Monitoring Extension
9th Nov 202011:05 amRNSSecond Price Monitoring Extn
9th Nov 202011:00 amRNSPrice Monitoring Extension
9th Nov 20209:05 amRNSSecond Price Monitoring Extn
9th Nov 20209:00 amRNSPrice Monitoring Extension
9th Nov 20207:00 amRNSIB and the Mayo Clinic enter into an Agreement
6th Nov 20204:35 pmRNSPrice Monitoring Extension
6th Nov 20202:05 pmRNSSecond Price Monitoring Extn
6th Nov 20202:00 pmRNSPrice Monitoring Extension
6th Nov 202011:05 amRNSSecond Price Monitoring Extn
6th Nov 202011:00 amRNSPrice Monitoring Extension
5th Nov 20204:41 pmRNSSecond Price Monitoring Extn
5th Nov 20204:36 pmRNSPrice Monitoring Extension
5th Nov 20209:00 amRNSPrice Monitoring Extension
5th Nov 20207:00 amRNSMontgomery Cancer Center Purchases IB's Software
4th Nov 20207:00 amRNSLSN Software Receives FDA Clearance
30th Oct 202011:05 amRNSSecond Price Monitoring Extn
30th Oct 202011:00 amRNSPrice Monitoring Extension
30th Oct 20207:00 amRNS"Gad Free" Imaging moves to Validation Testing
15th Oct 20207:00 amRNSIB Stroke
8th Oct 20203:41 pmRNSStoneChecker Update
24th Sep 202010:43 amRNSThe Benefits and Significance of IB Neuro
16th Sep 20207:00 amRNSKeck Medical Centre of USC Purchases IB's Software
10th Sep 20207:00 amRNSIB Trax™
4th Sep 20209:03 amRNS“Gad Free” Imaging - One Step Closer
7th Aug 20207:00 amRNSHalf-year Report
5th Aug 20204:41 pmRNSSecond Price Monitoring Extn
5th Aug 20204:35 pmRNSPrice Monitoring Extension
5th Aug 202011:05 amRNSSecond Price Monitoring Extn
5th Aug 202011:00 amRNSPrice Monitoring Extension
5th Aug 20209:53 amRNSStonechecker Update
27th Jul 20207:00 amRNSUpdate - IB Stroke
10th Jul 20207:00 amRNSNew Development Aims to Detect Tumor Infiltration
19th Jun 20207:00 amRNSIB, the Recognised National Standard in MRI DSC
15th Jun 202011:52 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.